Behavioural Experiments for Generalized Anxiety in Adolescents - Pilot Study

Launched by UNIVERSITE DU QUEBEC EN OUTAOUAIS · Feb 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Behavioural Experiments for Intolerance to Uncertainty in Adolescents (EC-IIA) for teens aged 14 to 18 who have Generalized Anxiety Disorder (GAD). GAD is a condition where individuals feel excessive worry and anxiety about various aspects of their lives, which can affect their daily activities, school performance, and relationships. The researchers believe that helping these young people learn to tolerate uncertainty, rather than avoiding it, could significantly reduce their anxiety.

To participate in the study, eligible teens must have a primary diagnosis of GAD and should not have changed their medication for a specific period before joining. They also should not be involved in other therapy or trials during this time. Participants will receive the new treatment and will be checked at different times for several months to see how well it works. This study aims to find out if this simpler and less costly treatment is effective and to learn more about how it helps manage anxiety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adolescents aged between 14 and 18 years; 2) primary diagnosis of Generalized Anxiety Disorder (GAD); 3) no change in type or dose of medication in the 4 to 12 weeks preceding entry into the study (4 weeks for benzodiazepines, 12 weeks for antidepressants, hypnotics, and psychostimulants); 4) willingness to maintain stable medication status during participation in the study; 5) absence of consumption of herbal products known to have effects on the central nervous system in the 2 weeks preceding entry into the study; 6) absence of evidence of suicidal intent (based on clinical judgment); 7) absence of evidence of current substance use, current or past schizophrenia, bipolar disorder, or organic mental disorder; 8) absence of current participation in other clinical trials (i.e., psychotherapeutic services); 9) absence of concurrent psychotherapy during the trial treatment phase; 10) absence of evidence of anxiety symptoms due to a general medical condition based on clinical judgment (e.g., clinical hyperthyroidism, hypoglycemia, anemia).